Basilea Pharmaceutica AG Cash Flow Conversion Efficiency
Basilea Pharmaceutica AG cash flow conversion efficiency. Based on the latest financial reports, Basilea Pharmaceutica AG (BSLN) has a cash flow conversion efficiency ratio of 0.305x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CHF39.03 Million ≈ $49.35 Million USD) by net assets (CHF127.94 Million ≈ $161.75 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Basilea Pharmaceutica AG (2002–2025)
Cash flow conversion efficiency of Basilea Pharmaceutica AG from 2002 to 2025. This chart illustrates how Basilea Pharmaceutica AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Basilea Pharmaceutica AG for real-time trading data and today's change.
Basilea Pharmaceutica AG Cash Flow Conversion Ratio Explained
Basilea Pharmaceutica AG cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Basilea Pharmaceutica AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Basilea Pharmaceutica AG ranked by their cash flow conversion efficiency. Also see Basilea Pharmaceutica AG stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Amsterdam Commodities NV
AS:ACOMO
|
0.125x |
|
Air New Zealand Ltd
AU:AIZ
|
0.117x |
|
JSE Limited
JSE:JSE
|
0.140x |
|
Guizhou Guihang Automotive Components Co Ltd
SHG:600523
|
-0.002x |
|
Placoplatre SA
PA:MLPLC
|
N/A |
|
Jiangsu Changbao Steeltube Co Ltd
SHE:002478
|
0.031x |
|
Guangdong Xinhui Meida Nylon Co Ltd
SHE:000782
|
0.116x |
|
Ability Opto-Electronics Technology Co Ltd
TWO:3362
|
-0.001x |
Annual Cash Flow Conversion Efficiency for Basilea Pharmaceutica AG (2002–2025)
The table below shows the annual cash flow conversion efficiency of Basilea Pharmaceutica AG from 2002 to 2025. Review Basilea Pharmaceutica AG (BSLN) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CHF127.94 Million ≈ $161.75 Million |
CHF62.09 Million ≈ $78.50 Million |
0.485x | -47.14% |
| 2024-12-31 | CHF81.00 Million ≈ $102.40 Million |
CHF74.36 Million ≈ $94.01 Million |
0.918x | +164.47% |
| 2023-12-31 | CHF-10.00 Million ≈ $-12.65 Million |
CHF14.24 Million ≈ $18.01 Million |
-1.424x | -318.08% |
| 2022-12-31 | CHF-20.71 Million ≈ $-26.19 Million |
CHF7.06 Million ≈ $8.92 Million |
-0.341x | -162.35% |
| 2021-12-31 | CHF-58.61 Million ≈ $-74.10 Million |
CHF-32.02 Million ≈ $-40.48 Million |
0.546x | +2.99% |
| 2020-12-31 | CHF-102.05 Million ≈ $-129.01 Million |
CHF-54.13 Million ≈ $-68.44 Million |
0.530x | -22.75% |
| 2019-12-31 | CHF-92.96 Million ≈ $-117.53 Million |
CHF-63.84 Million ≈ $-80.71 Million |
0.687x | -42.19% |
| 2018-12-31 | CHF-66.69 Million ≈ $-84.31 Million |
CHF-79.21 Million ≈ $-100.14 Million |
1.188x | +358.87% |
| 2017-12-31 | CHF-41.44 Million ≈ $-52.39 Million |
CHF19.01 Million ≈ $24.04 Million |
-0.459x | -121.41% |
| 2016-12-31 | CHF-35.00 Million ≈ $-44.25 Million |
CHF-75.00 Million ≈ $-94.82 Million |
2.143x | +146.97% |
| 2015-12-31 | CHF14.86 Million ≈ $18.78 Million |
CHF-67.78 Million ≈ $-85.69 Million |
-4.562x | -269.86% |
| 2014-12-31 | CHF57.93 Million ≈ $73.24 Million |
CHF-71.46 Million ≈ $-90.35 Million |
-1.234x | -47.01% |
| 2013-12-31 | CHF70.87 Million ≈ $89.60 Million |
CHF-59.47 Million ≈ $-75.19 Million |
-0.839x | -159.74% |
| 2012-12-31 | CHF105.50 Million ≈ $133.38 Million |
CHF148.17 Million ≈ $187.33 Million |
1.404x | +361.31% |
| 2011-12-31 | CHF153.27 Million ≈ $193.77 Million |
CHF-82.38 Million ≈ $-104.15 Million |
-0.537x | -205.96% |
| 2010-12-31 | CHF210.24 Million ≈ $265.80 Million |
CHF106.64 Million ≈ $134.82 Million |
0.507x | +143.29% |
| 2009-12-31 | CHF97.73 Million ≈ $123.56 Million |
CHF-114.51 Million ≈ $-144.77 Million |
-1.172x | -84.04% |
| 2008-12-31 | CHF199.74 Million ≈ $252.53 Million |
CHF-127.17 Million ≈ $-160.77 Million |
-0.637x | -170.10% |
| 2007-12-31 | CHF335.10 Million ≈ $423.66 Million |
CHF-78.99 Million ≈ $-99.86 Million |
-0.236x | +63.47% |
| 2006-12-31 | CHF112.31 Million ≈ $141.99 Million |
CHF-72.47 Million ≈ $-91.62 Million |
-0.645x | -415.05% |
| 2005-12-31 | CHF167.87 Million ≈ $212.23 Million |
CHF34.38 Million ≈ $43.47 Million |
0.205x | +166.86% |
| 2004-12-31 | CHF209.60 Million ≈ $264.99 Million |
CHF-64.20 Million ≈ $-81.17 Million |
-0.306x | +47.24% |
| 2003-12-31 | CHF90.29 Million ≈ $114.15 Million |
CHF-52.42 Million ≈ $-66.28 Million |
-0.581x | -13.63% |
| 2002-12-31 | CHF125.38 Million ≈ $158.51 Million |
CHF-64.07 Million ≈ $-81.00 Million |
-0.511x | -- |
About Basilea Pharmaceutica AG
Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. The company offers Cresemba (isavuconazole), an intravenous and oral antifungal for the treatment of invasive aspergillosis and mucormycosis; and Zevtera (ceftobiprole), an antibiotic for the treatment of pneumonia, Staphylococcus au… Read more